603368 Guangxi LiuYao Group
WatchlistGuangxi LiuYao Group News
Liuyao Group (603368.SH)'s application for a fixed increase in shares was approved by the China Securities Regulatory Commission
Liuyao Group (603368.SH) issued an announcement. The company recently received an announcement from the China Securities Regulatory Commission...
Declining Stock and Decent Financials: Is The Market Wrong About Guangxi LiuYao Group Co., Ltd (SHSE:603368)?
With its stock down 5.2% over the past week, it is easy to disregard Guangxi LiuYao Group (SHSE:603368). But if you pay close attention, you might find that its key financial indicators look quite d
Liuyao Group (603368.SH): The implementation of the SPD project for hospital equipment consumables will be further accelerated this year
On October 31, Gelonghui Group (603368.SH) said at an investor exchange conference that the company's market share of medical device consumables in Guangxi is low, and there is plenty of room for growth. Therefore, in recent years, the company has increased its market expansion efforts in medical device consumables and test reagents, strengthened business resource collaboration between the drug side and the device side, and jointly promoted the development of hospital customers for device consumables and test reagents and the implementation of hospital SPD projects. The company will further accelerate the implementation of the SPD project for hospital equipment and consumables this year. It plans to have 18-22 tertiary hospitals and 20-30 second-tier hospitals in Guangxi
Liuyao Group (603368.SH): By the end of the third quarter of this year, the company had developed nearly 200 customers
Gelonghui, October 31, Liuyao Group (603368.SH) said at an investor exchange conference that the company's current hospital development work is progressing in an orderly manner. By the end of the third quarter of this year, the company had developed nearly 200 customers, including some medical institutions in Guangxi and some regional medical institutions outside the province. Next, the company will further accelerate the market layout of core hospitals in the region and promote sales volume.
Liuyao Group (603368.SH): At present, it has completed the registration and listing of more than 400 varieties
On October 31, Gelonghui Group (603368.SH) said at an investor exchange conference that in terms of production and sales of traditional Chinese medicine formula granules, the company has now completed the registration and listing of more than 400 varieties. In addition to national standard varieties and Guangxi provincial standard varieties, companies are simultaneously carrying out filing work in Guangdong, Sichuan, Chongqing and other regions. In terms of market development, the company's traditional Chinese medicine formula granules have relied on the company's hospital channel advantages to carry out extensive hospitalization work.
[BT Financial Report Instantaneous Analysis] Liuyao Group's 2023 Three-Quarter Report: Steady Growth in Performance, Significant Increase in Cash Flow
This financial report was announced on 2023-10-25 16:20:02 Guangxi Liuyao Group Co., Ltd. (stock code: 603368), which is mainly engaged in pharmaceutical distribution business, covering two major business segments: wholesale and retail. At the same time, the company is also actively developing upstream pharmaceutical industry business and is committed to the production and development of traditional Chinese medicine-related products such as traditional Chinese medicine, proprietary Chinese medicines, and traditional Chinese medicine formula granules. Driven by both industry development and policy support, the company's performance has maintained steady growth. In terms of assets and liabilities, at the end of the third quarter of 2023, Liuyao Group's total assets were 20.737 billion yuan, compared with 18 at the end of the previous year
Review of the 2023 Third Quarter Report of Liuyao Group (603368): Steady growth in performance and significant improvement in cash flow
Investment Highlights Recently, the company released its three-quarter report for 2023. The company achieved operating income of 15.617 billion yuan from January to September 2023, a year-on-year increase of 9.80%; net profit attributable to shareholders of listed companies of 6.75
Liuyao Group (603368): Wholesale business maintains steady and rapid industrial business development
Event: In the first three quarters of 2023, Liuyao Group achieved revenue of 15.617 billion yuan, an increase of 9.80% over the previous year; net profit of 675 million yuan, an increase of 17.26% over the previous year. Q3 Steady growth, gross margin maintained
Liu Pharmaceutical Group (603368.SH) released results and net profit of 675 million yuan for the first three quarters, up 17.26% year-on-year
Liu Pharmaceutical Group (603368.SH) disclosed its report for the third quarter of 2023. The company achieved operating income during the reporting period...
Liu Pharmaceutical Group (603368): 3Q profit grew steadily and industrial business continued to expand
3Q23 Net profit maintained steady growth. Profitability improved. The company's 9M23 operating income/net profit attributed/net profit after deducting non-attributable net profit was 156.17/6.75/668 billion yuan, +9.8% /+17.3
Well-known fund managers Qiu Dongrong and Liu Yuanhai's latest operations revealed!
The three-quarter report on funds managed by famous fund managers such as Qiu Dongrong and Liu Yuanhai has been released!
Guangxi LiuYao Group Co., Ltd's (SHSE:603368) Stock Price Dropped 5.6% Last Week; Individual Investors Would Not Be Happy
Key Insights Guangxi LiuYao Group's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 21 investors have a ma
Tianfeng Securities: The pharmaceutical distribution sector performed well in the first half of the year, and the retail and distribution sector achieved good growth
The core logic of the pharmaceutical distribution industry comes from valuation restoration under policy optimization. It is recommended to look at the changing trends of enterprises from a medium-term perspective.
The production capacity of the Liuyao Group (603368.SH) traditional Chinese medicine formula granule project reached 800-1000 tons
Liu Pharmaceutical Group (603368.SH) announced that the company has produced traditional Chinese medicine formula granules as of September 22, 2023...
Investors Met With Slowing Returns on Capital At Guangxi LiuYao Group (SHSE:603368)
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in c
Liu Pharmaceutical Group (603368.SH): Its subsidiary, Wantong Pharmaceutical produces tea to remove stasis and strengthen the spleen. This product has the effects of clearing heat and strengthening the spleen, removing stasis and moisture
Glonghui, September 14, 丨 Liu Pharmaceutical Group (603368.SH) said on the investor interactive platform that in response to the current high incidence of hyperlipidemia caused by chronic diseases, metabolic diseases, unhealthy lifestyle and eating habits, obesity, etc., the company's Wantong Pharmaceutical produces spleen removal tea. This product has the effects of clearing heat and strengthening the spleen and removing moisture, and is mainly used as an adjuvant treatment for hyperlipidemia caused by moisture and heat blockage.
Liu Pharmaceutical Group (603368.SH): Will accelerate the implementation of the hospital equipment consumables SPD project with an investment amount of 410 million yuan
Liu Pharmaceutical Group (603368.SH) issued an announcement. The company held an investor exchange meeting. During the meeting, the company stated, 2...
Liu Yao Group (603368): Wholesale-side customer stickiness increases, industrial-side marketing results are shown
Investment highlights Recently, the company released its 2023 annual report. In the first half of 2023, the company achieved operating income of 10.344 billion yuan, an increase of 12.42% over the previous year; achieved net profit of 443 million yuan, a year-on-year increase of 20 million yuan
Liu Pharmaceutical Group (603368): Optimizing the Pharmaceutical Distribution Structure and Rapid Growth of the Pharmaceutical Industry
Event: In the first half of 2023, the company achieved operating income of RMB 10.344 billion, an increase of 12.42% over the previous year; realized net profit of RMB 443 million, an increase of 20.02% over the previous year. The pharmaceutical industry is developing rapidly:
Liu Pharmaceutical Group (603368.SH): Net profit for the first half of the year was 443 million yuan, up 20.02% year on year
Glonghui, August 28: Liu Pharmaceutical Group (603368.SH) announced its 2023 semi-annual report. During the reporting period, it achieved operating income of 10.344 billion yuan, up 12.42% year on year; net profit attributable to shareholders of listed companies was 443 million yuan, up 20.02% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 438 million yuan, up 20.13% year on year; basic earnings per share.